Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MJT.0000000000001169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Article Synopsis
- * Discontinuing immunosuppressants didn’t help her condition, but treatment with lenalidomide led to the disappearance of lymphoma cells and normalization of sIL2R levels, despite causing some pancytopenia (low blood cell counts).
- * After treatment with lenalidomide, the woman achieved complete remission and showed no signs of ATL relapse after 13 months, indicating lenalidomide could be an effective treatment for relapsed
Navigating the Nexus: Lenalidomide-Associated Thrombotic Thrombocytopenic Purpura.
Cureus
June 2024
Internal Medicine, Piedmont Athens Regional Medical Center, Athens, USA.
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy (TMA) marked by thrombocytopenia, microangiopathic hemolytic anemia, and microvascular thrombosis leading to end-organ damage. While TTP commonly results from hereditary or acquired ADAMTS13 deficiency, its association with lenalidomide is notably rare. The link between lenalidomide and TMA is unclear and requires more studies, given the high mortality risk associated with TTP.
View Article and Find Full Text PDFSevere Lenalidomide-Associated Hyperbilirubinemia.
Cureus
January 2023
Hematology and Oncology, MedStar Georgetown University Hospital, Washington, D.C., USA.
Immunomodulatory drugs (IMids), such as thalidomide and lenalidomide, are used to treat plasma cell neoplasms and B-cell malignancies. We present a case of severe direct hyperbilirubinemia in a patient taking lenalidomide-based therapy for plasmacytoma. Imaging was unrevealing, and liver biopsy showed only mild sinusoidal dilation.
View Article and Find Full Text PDFTreatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma.
J Investig Med High Impact Case Rep
October 2022
Appalachian Regional Healthcare, Hazard, KY, USA.
Secondary malignancies including leukemia are an increasing concern in patients with prior primary malignancies treated with alkylating agents or topoisomerase II inhibitors. These can also be referred to as therapy-related leukemia. Therapy-related leukemia most commonly results in myelodysplastic syndrome or acute myeloid leukemia.
View Article and Find Full Text PDFThree Cases of Lenalidomide Therapy for Multiple Myeloma and Subsequent Development of Secondary B-ALL.
J Oncol Pharm Pract
July 2022
Allegheny Health Network Cancer Institute, Division of Hematology and Cellular Therapy, Pittsburgh, PA, United States.
Introduction: Multiple myeloma (MM) is the second most common hematological malignancy, accounting for 1% of all cancers, with median age of diagnosis between 66-70 years. MM remains incurable despite advances in treatment over time. Lenalidomide is an important medication used in induction therapy for MM and is also used for maintenance therapy for standard risk patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!